We do the research and development of diagnostic products (currently) based on a well-defined understanding of immune tolerance (IT).
Our first product is a comprehensive test for the diagnosis and monitoring of TB. It represents a model for developing similar products for any pathogenic micro-organism including viruses and parasites in humans and animals.
The second product is a screening test for colorectal cancer. Cancer is different than pathogenic microorganisms. Cancer biomarkers proteins exist in normal cells. Finding the diagnostic protein biomarker requires a methodology and technology. Erythra developed the methodology that facilitates this process which is based on the Immune Tolerance concepts discovered.
The advantages of Erythra diagnostic products are sensitivity expressed by the ability to diagnose early during the disease pathogenesis, simplicity by using the lateral flow chromatographic assay, and affordable as it does not need expensive laboratory equipment.
Curre...
We do the research and development of diagnostic products (currently) based on a well-defined understanding of immune tolerance (IT).
Our first product is a comprehensive test for the diagnosis and monitoring of TB. It represents a model for developing similar products for any pathogenic micro-organism including viruses and parasites in humans and animals.
The second product is a screening test for colorectal cancer. Cancer is different than pathogenic microorganisms. Cancer biomarkers proteins exist in normal cells. Finding the diagnostic protein biomarker requires a methodology and technology. Erythra developed the methodology that facilitates this process which is based on the Immune Tolerance concepts discovered.
The advantages of Erythra diagnostic products are sensitivity expressed by the ability to diagnose early during the disease pathogenesis, simplicity by using the lateral flow chromatographic assay, and affordable as it does not need expensive laboratory equipment.
Currently, we are involved in developing a screening test for breast cancer and a treatment susceptibility to PD1 monoclonal antibodies and identification of cure.
More information

Employees

Mahmoud Rafea
Admin
Mahmoud Rafea CEO Double qualified, graduated from the faculty of medicine, have M.Sc. in Clinical Pathology and PhD AI.

Recommendations

God bless you
We are prying for you